Cite
HARVARD Citation
El Hachem, G. et al. (2021). Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Expert review of anticancer therapy. 21 (1), pp. 81-92. [Online].